VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, announced that two leading independent proxy advisory firms have provided voting recommendations for upcoming annual meeting of stockholders. According to the announcement, the two firms — Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (Glass Lewis) — suggest VistaGen stockholders vote for Proposal No. 5. If approved, the proposal provides VTGN’s board of directors with the option to implement a reverse stock split of the company’s issued and outstanding common stock if needed to maintain the company’s listing on the NASDAQ. VistaGen’s 2022 annual meeting is slated for Oct. 14, 2022, at 10 a.m. PT. “We are pleased that both ISS and Glass Lewis, the leading independent proxy advisory firms, support our board’s recommendation that stockholders vote for Proposal No. 5,” said VistaGen CEO Shawn Singh in the press release. “Each stockholder’s vote is important, so we strongly encourage each investor to follow the recommendations of ISS and Glass Lewis and vote for Proposal No. 5 as promptly as possible. Approval of Proposal No. 5 will provide the flexibility that will be essential should we need to utilize this tool to maintain our NASDAQ listing. Confidence in our ability maintain our NASDAQ listing will be an important complement to our ongoing efforts to enhance market awareness of the potential of our pipeline to improve the millions of lives suffering from mental illness and other CNS disorders and deliver value to our stockholders.”
To view the full press release, visit https://ibn.fm/OGZUw
About VistaGen Therapeutics Inc.
VistaGen is a late clinical-stage biopharmaceutical aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than those that are currently available. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless and tasteless investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. VistaGen is passionate about transforming mental-health care and redefining what is possible in the treatment of anxiety and depression. For more information about the company, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
